Major Biotechs See a Rising Tide in Short Interest
The November 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 78
Health Insurance Helps You Live Longer
A new study indicates that the individual mandate portion of the Affordable Care Act (Obamacare) did encourage more people to get insurance coverage. And some Americans will live longer because of it.
Will This FDA Decision Set Off These Late-Stage Dermatitis Studies?
Dermira shares jumped on Tuesday after the firm announced that the FDA has granted Fast Track designation for lebrikizumab, its treatment moderate-to-severe atopic dermatitis.
More Americans Delay Medical Treatment Because of Cost
Some sick Americans have probably become sicker because they do not believe they can pay for appropriate treatment. And the trend has spiked in the past year.
Why Fate Therapeutics Is One of ASH’s Biggest Winners
Fate Therapeutics shares jumped on Monday after the firm announced new preclinical data for its off-the-shelf, multi-antigen targeting natural killer cell product candidate derived from a clonal master engineered induced pluripotent stem cell line.
Why These 3 Biotechs More Than Doubled on Monday
Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a few of these standouts…
Is the Sage Therapeutics Implosion Overblown?
Sage Therapeutics shareholders took a bath on Thursday after results from its late-stage major depressive disorder trial came public.
Thursday’s Biggest Biotech Movers
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Why This Transfusion-Dependent Beta-Thalassemia Trial Is Taking Off
Protagonist Therapeutics shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia.
Are Audentes Shareholders Getting Enough in the Acquisition?
Audentes Therapeutics shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just over three years, this acquisition offers a…
How Aslan Pharma Is Capitalizing on Its Huge Atopic Dermatitis Success
Aslan Pharmaceuticals has been on a roller coaster for the past two weeks. Now the stock is coming back to earth, with the company announcing that it will be capitalizing on these gains with…
Why Mixed Results From This Chronic Kidney Disease Study Aren’t That Great
Cara Therapeutics shares were crushed on Tuesday after the firm announced results from its midstage trial in patients with chronic kidney disease.
Why Investors Shouldn’t Sleep on This Narcolepsy Study
Axsome Therapeutics shares jumped early on Tuesday after the firm announced positive results from its midstage narcolepsy trial.
Study: The Poor Get Less Sleep, Leading to Greater Risk of Heart Disease
Research shows that a lack of sleep is a significant factor in the occurrence of heart disease among low-income people.
Why This Atopic Dermatitis Study Was So Well Received
Aslan Pharmaceuticals shares jumped on Monday after the firm announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of its treatment of moderate-to-severe atopic dermatitis.